Compare Dow Inc (DOW) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Novo Nordisk A/S — how do they compare? Dow Inc trades at $28.55 (market cap $20.65B), while Novo Nordisk A/S trades at $38.49 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 8× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Novo Nordisk A/S for 116 Days on average.
| DOW | NVO | |
|---|---|---|
Market Cap | $20.65B | $165.31B |
Volume | 14,126,943 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $63.98 |
52-Week Low | $20.65 | $35.29 |
Typical Hold Time | 82 Days | 116 Days |
Enterprise Value | $36.34B | $179.56B |
Dividend Yield | 4.9% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.80, up 3.71% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite negative profitability, with ROE at -7.86% and net income margin at -3.13%. Recent earnings have beaten expectations, but revenue declined to $39.97B in 2025. Cash flow improved to $1.69B net in 2025, though operating cash flow remains pressured.
Outlook is mixed: analyst consensus is a hold with a $34.22 price target, implying 19% upside, but weak margins and declining revenue pose risks. The dividend yield offers income support, but investors face headwinds from cyclical chemical demand and high debt levels, with debt-to-asset ratio rising to 29.87% in 2025.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
